Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and the Keck School of Medicine of USC and Keck Medicine of USC, today announced a ...
The initiative will apply its massive, multimodal dataset to build models that aim to improve diagnostic, prognostic, and predictive modeling CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (TEM), a ...
Tempus AI (TEM) stock fell 7.33% after announcing a precision medicine partnership with USC Keck Medicine covering 1.5M+ ...
New RNA-based algorithm is now available with the xR assay “This program is truly the intersection of all three of our business units – genomics, AI applications, and data – leveraging our deep ...
Tempus AI has gained clearance for software that uses artificial intelligence to identify patients who may have the cardiovascular condition of low left ventricular ejection fraction, or LVEF. The ...
Tempus AI is a healthcare technology company that utilizes artificial intelligence technology to collect and analyze molecular, clinical, and genomic data. It collects clinical and genomic databases ...
CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced a strategic collaboration with Daiichi Sankyo (TSE: 4568) aimed at accelerating ...
Tempus AI, Inc. (NASDAQ:TEM) is one of the top 10 medical AI companies to buy according to analysts. On July 16, the company confirmed that it had received clearance from the US Food and Drug ...
Tempus and New York City-based NYU Langone Health have formed a multi-year strategic collaboration to advance cancer research through molecular profiling and data-driven insights. The partnership will ...
Great news for Tempus AI stock! The company has just received FDA approval for an upgraded version of its Tempus Pixel platform — a cardiac imaging system that uses advanced AI to deliver highly ...
Tempus AI (NasdaqGS:TEM) and Daiichi Sankyo announced a collaboration to use Tempus' AI models in oncology drug development. The partnership centers on a novel antibody drug conjugate program, aiming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results